Clinical Leader, a publication dedicated to streamlining clinical trials, has recently profiled the introduction of AD-214, AdAlta’s second generation lead candidate, with improve therapeutic and commercial potential. The article discusses the decision to delay the clinical trial by 12 months, the factors involved in the decision and suggests that “while this postponement could be painful for the company in the short run, the longer-term outcome will be a superior drug candidate for AdAlta, its partners, and patients”.
The article, titled ‘What Would Convince You To Delay Your Trial For 12 Months?‘ can be accessed here.
